GLASGOW, Scotland, June 4, 2026 /PRNewswire/ — New findings from the landmark FLOW trial, introduced on the 63rd ERA Congress, present that once-weekly semaglutide considerably improved health-related high quality of life in adults with sort 2 diabetes (T2D) and power kidney illness (CKD), equal to round eight further days in full well being per 12 months.
The trial beforehand demonstrated that semaglutide diminished the danger of main kidney illness occasions by 24% and all-cause mortality by 20% in contrast with placebo over a median remedy period of three.4 years. This new evaluation offers complementary patient-centred proof, exhibiting that the advantages of semaglutide might prolong past conventional medical outcomes to how sufferers really feel and performance in on a regular basis life.
For individuals dwelling with each T2D and CKD, signs, remedy burden and diminished bodily functioning can considerably have an effect on day-to-day well-being, making high quality of life an more and more vital remedy objective.
Amongst 3,533 randomised members within the FLOW trial, 1,767 obtained semaglutide and 1,766 obtained placebo. Well being-related high quality of life was assessed utilizing the EQ-5D-5L questionnaire, a patient-reported measure of well being standing and well-being overlaying mobility, self-care, typical actions, ache/discomfort, anxiousness/despair, and general well being notion.
After two years of remedy, well being utility scores – which vary from 0 (demise) to 1 (good well being) – remained steady within the semaglutide group however declined in these receiving placebo. The estimated remedy distinction of +0.021 (p=0.0001) corresponded to roughly eight further days per 12 months spent in full well being.
Self-rated common well being scores additionally improved with semaglutide however worsened with placebo, with a big remedy distinction of +2.15 (p<0.0001), once more changing into worse over time with placebo whereas steady on semaglutide.
4 of the 5 areas assessed by the questionnaire (mobility, self-care, typical actions, and ache/discomfort) improved considerably with semaglutide in contrast with placebo. No important distinction was noticed in anxiousness/despair. Advantages had been broadly constant throughout affected person subgroups.
“We had been shocked by the extent of the quality-of-life advantages seen with semaglutide, as a result of they weren’t solely clinically significant however constantly skilled throughout a number of features of each day life, together with bodily functioning and general well-being,” mentioned Professor Johannes Mann, examine lead creator.
“We had been unsure about quality-of-life outcomes as a result of gastrointestinal negative effects are widespread with GLP-1 receptor agonists,” Prof. Mann furthered. “Our findings affirm that the advantages of semaglutide in power kidney illness prolong past conventional medical endpoints to subjective outcomes that matter on to sufferers.”
